Trials / Active Not Recruiting
Active Not RecruitingNCT06299124
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
A Phase I Study Evaluating Safety and Tolerability of RGT-419B Monotherapy in Chinese Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer or Other Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Regor Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RGT-419B | RGT-419B will be administered orally |
Timeline
- Start date
- 2023-04-17
- Primary completion
- 2025-07-30
- Completion
- 2025-07-30
- First posted
- 2024-03-07
- Last updated
- 2025-01-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06299124. Inclusion in this directory is not an endorsement.